| Literature DB >> 35259826 |
Tiam M Saffari1, Sara Saffari1, Krishna S Vyas2, Samir Mardini2, Alexander Y Shin3.
Abstract
The application of autologous fat grafting in reconstructive surgery is commonly used to improve functional form. This review aims to provide an overview of the scientific evidence on the biology of adipose tissue, the role of adipose-derived stem cells, and the indications of adipose tissue grafting in peripheral nerve surgery. Adipose tissue is easily accessible through the lower abdomen and inner thighs. Non-vascularized adipose tissue grafting does not support oxidative and ischemic stress, resulting in variable survival of adipocytes within the first 24 hours. Enrichment of adipose tissue with a stromal vascular fraction is purported to increase the number of adipose-derived stem cells and is postulated to augment the long-term stability of adipose tissue grafts. Basic science nerve research suggests an increase in nerve regeneration and nerve revascularization, and a decrease in nerve fibrosis after the addition of adipose-derived stem cells or adipose tissue. In clinical studies, the use of autologous lipofilling is mostly applied to secondary carpal tunnel release revisions with promising results. Since the use of adipose-derived stem cells in peripheral nerve reconstruction is relatively new, more studies are needed to explore safety and long-term effects on peripheral nerve regeneration. The Food and Drug Administration stipulates that adipose-derived stem cell transplantation should be minimally manipulated, enzyme-free, and used in the same surgical procedure, e.g. adipose tissue grafts that contain native adipose-derived stem cells or stromal vascular fraction. Future research may be shifted towards the use of tissue-engineered adipose tissue to create a supportive microenvironment for autologous graft survival. Shelf-ready alternatives could be enhanced with adipose-derived stem cells or growth factors and eliminate the need for adipose tissue harvest.Entities:
Keywords: adipose tissue; adipose-derived stem cells; angiogenesis; autologous fat grafting; nerve injury; nerve regeneration; paracrine environment; peripheral nerve reconstruction; stem cell secretome; tissue engineering
Year: 2022 PMID: 35259826 PMCID: PMC9083182 DOI: 10.4103/1673-5374.336870
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 6.058
Summary of mesenchymal stem cell (MSC) sources and cell surface markers
| Origin of MSCs | Expressed in MSCs | Not expressed in MSCs |
|---|---|---|
| Adipose tissue | CD90, CD44, CD29, CD105, CD13, CD73, CD166, CD10, CD49e, CD59 | CD31, CD45, CD14, CD11b, CD34, CD19, CD56, CD146 |
| Bone marrow | CD90, CD105, CD73 | CD45, CD14, CD34 |
| Dental pulp | CD90, CD44, CD29, CD105 | CD45, CD14, CD34 |
| Peripheral blood | CD90, CD44, CD105 | CD45, CD133 |
| Skin | CD90, CD44, CD105, CD73, CD166 | CD45, CD34 |
|
| ||
| CD29, CD40, CD44 | Expressed across all species. | |
| CD45 | Not expressed, across all species. | |
| CD19 | Only not expressed in humans. | |
| CD49e, CD59 | Only expressed in humans. | |
| CD90 | Expressed in humans, pigs and rats. Less expressed in horses and sheep. Not expressed in mice. | |
| CD166 | Only expressed in humans, rats and sheep. | |
An overview of cell surface markers in different tissues is presented. A summary of differences between species is also given, comparing humans to horses, sheep, pigs, rats, and mice (Uder et al., 2018).